Long-Lived, Lifesaving: Cracking the Code on Immune Memory

Review written by: Roshni Kadam

Could the next pandemic be manageable instead of catastrophic? Vaccination is one of the most effective tools for protecting public health by preventing disease and helping control global pandemic outbreaks. It works by introducing a vaccine antigen: a part of disease-causing organism, or a version which is not dangerous that trains the immune system to recognize and fight off future infections. Vaccination induces long term immunity called the humoral immunity by driving germinal center reactions which are located inside the B-cell follicles of secondary lymphoid organ, activating antigen-specific memory B cells and LLPCs (long-lived plasma cells). The initial recognition of the any antigen is carried out by the innate immune system, the body's first line of defense against infection. Innate immune cells detect invaders through pattern recognition receptors (PRRs), which recognize conserved molecular signatures: pathogen-associated molecular patterns (PAMPs) displayed on pathogens. Specialized innate immune cells like antigen presenting cells such as dendritic cells (DCs) phagocytose the antigen, break it down into peptide fragments, and present these peptides on MHC class II molecules which are molecules present specifically on antigen presenting cells. As innate cues get stronger, more signals are released, further activating the dendritic cells that leads to upregulation of MHC molecules. This allows antigen presentation to antigen specific naïve B cells and T cells, activating them further. B cells then get activated in the follicle, where they migrate to the T-cell and B-cell junction and interact with T helper cells called follicular T helper cells. These specialized cells promote entry into the dark zone of the germinal center, where B cells undergo somatic hypermutation: an important process in which the B-cell receptor (BCR) mutates, producing receptors unique to various antigens. On the other hand, another region of the germinal center, the light zone, is responsible for antigen-driven selection, resulting in the differentiation of memory B cells (MBC) and LLPCs. Factors that impact LLPC differentiation include the initial BCR–antigen interaction and BCR affinity, BCR signaling, cytokine signaling, PAMP engagement like Toll-like receptor (TLR) and ligation-induced signaling. Although the timing and interdependence of these factors remain unclear. LLPCs reside in lymphoid tissues such as the bone marrow and GALT (gut-associated lymphoid tissue), where they secrete neutralizing antibodies for decades. These neutralizing antibodies are crucial for protection against recurring infection and are therefore important for vaccine development.

Figure. Current approved vaccine platforms.

The field's understanding of LLPC generation and differentiation from germinal center reactions as well as their migration, niche homing, and maintenance remains limited. A general understanding of what drives the LLPC response is therefore important for strategic vaccine development, since a strong LLPC response is required to sustain vaccine-mediated protection. Progress in this field is being fast-forwarded by the advent of new tools. Technologies like nanovials, nanorods, and techniques such as Ig trap and TRAPnSeq are starting to close this gap, letting researchers study these cells one at a time and confirm they are responding to the antigen in question. These tools are still new, but they are promising for filling in what remains unknown. Merck’s Infectious Diseases and Vaccines division has synthesized the field's current understanding of LLPC biology. The same research team has also contributed original experimental work in this space separately testing how vaccine delivery route affects LLPC generation in an RSV vaccine model, applying similar principles in practice. This new wave of research and technology, then, could be one piece of what helps us prevent or at least respond faster to future pandemics.

---

READ MORE:

Cusimano G, Staupe RP, Sullivan NL. Emerging novel methodologies to understand and strategically target long-lived plasma cells in vaccine design to induce durable immunity. Front Immunol. 2026 Feb 6;16:1680375. doi: 10.3389/fimmu.2025.1680375. PMID: 41726181; PMCID: PMC12920446.